Protagonist Therapeutics Inc PTGX Stock Analysis

About Protagonist Therapeutics Inc

Protagonist Therapeutics is a late-stage development biopharmaceutical company focused on peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), licensed to Johnson & Johnson, is the first targeted oral peptide designed to selectively block the IL-23 receptor. Icotrokinra has successfully completed two Phase 3 psoriasis (PsO) studies (ICONIC-LEAD and ICONIC-TOTAL) and is currently in three additional Phase 3 PsO studies (ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and a Postular/Erythrodermic PSO study) and a Phase 2b ulcerative colitis study (ANTHEM-UC). Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral anti-obesity peptides, and an oral hepcidin mimetic/ferroportin blocker.